Dendritic Cell Immunotherapy of Metastatic Melanoma - A Phase I Trial

NCT00003792 Phase 1 COMPLETED

RATIONALE: Vaccines made from a person's white blood cells and melanoma cells may make the body build an immune response and kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have metastatic melanoma.

Details

Lead sponsor	Baylor Health Care System
Phase	Phase 1
Status	COMPLETED
Start date	1999-04
Completion	2006-10

Conditions

• Melanoma (Skin)

Interventions

• MART-1 antigen
• filgrastim
• flu matrix peptide p58-66
• gp100 antigen
• recombinant MAGE-3.1 antigen
• tyrosinase peptide
• in vitro-treated peripheral blood stem cell transplantation

Countries

United States